Objection: Marketing authorisation amendment for Gardasil 9

This procedure involves a formal objection to a change in the marketing authorisation for Gardasil 9, a vaccine used to prevent certain types of human papillomavirus (HPV). It ensures that the regulatory updates for this medicinal product meet the necessary safety and efficacy standards for public use.

This affects healthcare providers and patients who rely on HPV vaccinations, as well as the pharmaceutical manufacturer responsible for the product's distribution in the EU.